BenevolentAI is a clinical-stage company specializing in AI-enabled drug discovery and development. By leveraging its advanced AI platform alongside scientific expertise and laboratory capabilities, the company aims to create novel drug candidates that demonstrate a higher likelihood of clinical success compared to traditional approaches. The Benevolent Platform supports a robust pipeline that includes over 20 drug programs, encompassing all stages from target discovery to clinical studies. Additionally, BenevolentAI collaborates with major pharmaceutical companies and leading research and charitable institutions to enhance its research efforts. The company is headquartered in London, with research facilities in Cambridge and an office in New York.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.